^LISBON, Portugal, Sept. 01, 2023 (GLOBE NEWSWIRE) — SOMAÍ Pharmaceuticals
Unipessoal LDA (the “Company” or “SOMAÍ”), the largest European
Manufacturer of pharmaceutical cannabis products, announces that it has been awarded the
Portuguese health authority INFRAMED approved its facility in
Lisbon, Portugal (approval number 42/V01 dated 08/25/2023). This
Approval allows the company to offer medicinal cannabis products
manufacture, import and export to numerous global markets,
and represents a significant step in the direction of the company
revenue generation. The company also announces that it
successfully raised EUR 5 million in new capital to finance its
ambitious growth plans.
With this INFRAMED approval, the company receives a GMP certificate part I
and Part II so that it can implement its plan to launch its own distribution channels in
Owning Australia and Germany, distribution partnerships in eight
other countries and at the same time a comprehensive brand for
to develop medical cannabis products. SOMAÍ aims to
To be a unique brand that meets all the requirements of doctors and patients
met by different delivery systems and novel formulations.
Michael Sassano, Founder and CEO of SOMAÍ:?In November 2021 we started with the
construction started. 12 months later, after the initial inspection, we have production
recorded. By now having the full GMP certificate part I and part II
received, we proved that it is possible in less than two
years of bringing pharmaceutical products to market. In addition, will
not only our products that have been completed since the beginning of the year
brought to the market, but we continue to work on a complete one
Next-generation product line designed to meet the future needs of the
patient based.”
Anton Nakhodkin, Board Member and Managing Director:?Our focus has shifted
move from development to full commercialization and growth by we
serving all current major markets and smaller and emerging markets thereon
prepare to open up to medicinal cannabis. Management has
all goals achieved and exceeded and another 5 million euros in new ones
Investments secured for building an international sales network.”
SOMAÍ remains extremely confident that the medical
Ready-to-dose cannabis products has enormous potential. With the
largest product range, SOMAÍ invests in this future, and the company
is already seeing global demand and interest in
its products, both in existing and new markets.
About SOMAÍ Pharmaceuticals Ltd.
SOMAÍ Pharmaceuticals LTD is a European pharmaceutical and
Biotechnology company specializing in manufacturing in Lisbon, Portugal
and the global distribution of EU-GMP certified cannabinoid containing products
Drugs focused. SOMAÍ puts the emphasis on scientific
pharmacological applications with EU GMP standards to produce preparations for the
deliver to the endocannabinoid system. SOMAÍ operates the largest and
most advanced cannabinoid manufacturing facility in the EU producing pharmaceuticals and
manufactures registered active pharmaceutical ingredients. Find more information
Visit the SOMAÍ website (https://somaipharma.eu/).
Business contact:
George Bellow
Chief Operations Officer
[email protected] (mailto:[email protected])
Press contact:
Natalia Garnina
Marketing Manager
[email protected] (mailto:[email protected])
A photo accompanying this notice is available at:
https://www.globenewswire.com/NewsRoom/AttachmentNg/175d01ab-a170-4483-bd77-
aa5417018e1c
°